Tamiflu

Generic Tamiflu (Oseltamivir) is an antiviral medication that blocks the actions of influenza virus types A and B in your body. Oseltamivir is used to treat influenza in people 2 weeks of age and older who have had flu symptoms for 2 days or less. It may also be given to prevent influenza in people who are at least 1 year old, who may be exposed but do not yet have symptoms. Oseltamivir will not treat the common cold.

Product dosage: 75 mg
Package (num)	Per cap	Price	Buy
10	$6.60	$66.00 (0%)	🛒 Add to cart
20	$6.15	$132.00 $123.00 (7%)	🛒 Add to cart
30	$5.67	$198.00 $170.00 (14%)	🛒 Add to cart
60	$5.22	$396.00 $313.00 (21%)	🛒 Add to cart
90	$4.74 Best per cap	$594.00 $427.00 (28%)	🛒 Add to cart
Synonyms Oseltamivir Antiflu Tamiflu

Tamiflu (oseltamivir phosphate) is an FDA-approved antiviral medication specifically formulated for the treatment and prevention of influenza types A and B. It belongs to the class of neuraminidase inhibitors, which work by blocking the action of the viral neuraminidase enzyme, a critical component for the replication and spread of the influenza virus within the respiratory tract. By inhibiting this enzyme, Tamiflu reduces the duration and severity of flu symptoms and helps prevent serious complications, particularly in high-risk populations. Its efficacy is maximized when initiated within 48 hours of symptom onset, making timely diagnosis and intervention crucial.

Features

• Active ingredient: Oseltamivir phosphate
• Available formulations: Oral capsules (30 mg, 45 mg, 75 mg) and oral suspension (6 mg/mL)
• Prescription-only medication
• Manufactured under stringent quality control standards
• Suitable for adults and pediatric patients aged 2 weeks and older
• Rapid systemic absorption with peak plasma concentrations within 3–4 hours

Benefits

• Reduces the duration of influenza symptoms by approximately one day when treatment is started within 48 hours of onset
• Lowers the risk of influenza-related complications such as pneumonia, bronchitis, and hospitalization
• Effective for seasonal influenza prophylaxis in individuals aged 1 year and older
• Helps decrease viral shedding, potentially reducing transmission to others
• Supported by extensive clinical trial data and real-world evidence
• Available in both capsule and liquid forms for ease of administration across age groups

Common use

Tamiflu is indicated for the treatment of uncomplicated acute influenza in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. It is also approved for the prophylaxis of influenza in patients 1 year of age and older. The medication is most effective against influenza A and B viruses and is commonly prescribed during seasonal flu outbreaks or in specific scenarios such as household outbreaks or immunocompromised settings. It is not a substitute for annual influenza vaccination but serves as an adjunct therapeutic option.

Dosage and direction

Dosage varies based on indication (treatment vs. prophylaxis), patient age, and renal function. For treatment of influenza in adults and adolescents (13 years and older), the standard dose is 75 mg twice daily for 5 days. For pediatric patients, weight-based dosing is applied. For prophylaxis, the recommended dose is 75 mg once daily for at least 10 days following contact with an infected individual or up to 6 weeks during a community outbreak. Tamiflu may be taken with or without food; however, administration with food may improve gastrointestinal tolerance. The oral suspension must be shaken well before each use, and doses should be measured using the supplied dispenser.

Precautions

Tamiflu is not a substitute for influenza vaccination. Use with caution in patients with renal impairment; dosage adjustment is required for creatinine clearance below 60 mL/min. There is a risk of neuropsychiatric events, such as delirium and abnormal behavior, primarily reported in pediatric patients. Monitor patients, especially children and adolescents, for signs of unusual behavior. Use during pregnancy only if clearly needed; animal studies have not shown direct harmful effects, but human data are limited. Exercise caution in patients with chronic cardiac or respiratory conditions due to the potential for complication exacerbation.

Contraindications

Tamiflu is contraindicated in patients with known hypersensitivity to oseltamivir phosphate or any component of the formulation. It should not be used in patients with severe renal impairment (creatinine clearance <10 mL/min) who are not undergoing dialysis. Avoid use in infants under 2 weeks of age due to limited safety and efficacy data.

Possible side effect

Common side effects include nausea, vomiting, diarrhea, headache, and abdominal pain. These are generally mild to moderate and often resolve without intervention. Less frequently, patients may experience dizziness, fatigue, or insomnia. Rare but serious side effects include severe skin reactions (e.g., Stevens-Johnson syndrome), anaphylaxis, and neuropsychiatric events (e.g., confusion, hallucinations, self-injury). Patients should seek immediate medical attention if any severe reactions occur.

Drug interaction

No clinically significant drug interactions have been identified in studies. However, caution is advised when co-administering with drugs that compete for renal excretion, such as probenecid, which may increase oseltamivir concentrations. Tamiflu is not known to interact with common analgesics, antipyretics, or antibiotics, but always inform your healthcare provider of all medications being taken.

Missed dose

If a dose is missed, take it as soon as possible unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Resume the regular dosing schedule. Consistent adherence is important for optimal efficacy, especially in the treatment regimen.

Overdose

There is no specific antidote for Tamiflu overdose. Single doses up to 1000 mg have been associated with nausea and vomiting. Management should include supportive care and symptomatic treatment. Hemodialysis removes oseltamivir and its active metabolite; consider it in cases of significant overdose, particularly in patients with renal impairment.

Storage

Store Tamiflu capsules at room temperature (15–30°C or 59–86°F) in a dry place. Keep the oral suspension at room temperature or refrigerate (2–8°C or 36–46°F); do not freeze. Discard any unused oral suspension after 10 days if stored at room temperature or 17 days if refrigerated. Keep all medications out of reach of children and pets.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or making changes to your treatment plan. Individual responses to Tamiflu may vary based on health status, viral strain, and timing of administration.

Reviews

Clinical studies and post-marketing surveillance demonstrate that Tamiflu is generally well-tolerated and effective in reducing the duration and severity of influenza symptoms when used appropriately. Many healthcare professionals endorse its use in high-risk patients and during widespread outbreaks. Patient reports often highlight symptom improvement within 24–48 hours of initiation, though gastrointestinal side effects are occasionally noted. Overall, it remains a cornerstone in influenza management protocols worldwide.